<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ISTALOL - timolol maleate solution </strong><br>ISTA PHARMACEUTICALS, INC.<br></p></div>
<h1>ISTALOL<span class="Sup">®</span><br>(timolol maleate ophthalmic solution) 0.5%<br>Sterile</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_2B97B806-490F-42DF-9F2C-520A4E5F0002"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ISTALOL (timolol maleate ophthalmic solution) 0.5% is a non-selective beta-adrenergic receptor blocking agent.  Its chemical name is (-)-1-(<span class="Italics">tert</span>-butylamino) –3- [(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt).  Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer.  The optical rotation of timolol maleate is:</p>
<p>                  25º<br>[α]              in 1.0N HCl (C = 5%) = -12.2º (-11.7º to –12.5º)<br>                  405 nm</p>
<p>Its molecular formula is C<span class="Sub">13</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S-C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and its structural formula is:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa20dc-b181-48be-83ce-d66a83753878&amp;name=istalol-01.jpg"></div>
<p>Timolol maleate has a molecular weight of 432.49.  It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol.  ISTALOL is stable at room temperature.  ISTALOL ophthalmic solution is supplied as a sterile, isotonic, buffered, aqueous solution of timolol maleate in a single strength.  It has a pH of 6.5-7.5 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 275-330 mOsm/kg. </p>
<p>Each mL of ISTALOL contains 5 mg of timolol (6.8 mg of timolol maleate).  Inactive ingredients: monobasic sodium phosphate monohydrate, potassium sorbate 0.47%, sodium chloride, sodium hydroxide, and purified water.  Benzalkonium chloride 0.005% is added as preservative.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_38486F21-5723-4583-8B7A-8DC74ABFEB18"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D9FA826E-6CAC-431E-9D2D-94CC8931BAFC"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Timolol maleate is a beta<span class="Sub">1</span> and beta<span class="Sub">2</span> (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.</p>
<p>Beta-adrenergic receptor blockade reduces <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in both healthy subjects and patients with heart disease.  In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.</p>
<p>Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity.  Such an effect in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or other bronchospastic conditions is potentially dangerous. </p>
<p>ISTALOL ophthalmic solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss.  The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>.</p>
<p>The onset of reduction in intraocular pressure following administration of ISTALOL can usually be detected within one-half hour after a single dose.  The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure lowering effect of ISTALOL is well maintained.</p>
<p>The precise mechanism of the ocular hypotensive action of ISTALOL is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation.  However, in some studies a slight increase in outflow facility was also observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_CF798455-F3C8-4B6D-837A-AB7EBFF50FFC"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">In a study of plasma drug concentration in 12 healthy subjects, the systemic exposure to timolol was determined following twice daily administration of ISTALOL (exaggerated regimen) or timolol maleate ophthalmic solution 0.5% (standard regimen) for eight days. With ISTALOL, mean plasma concentrations of timolol were 0.68 ng/mL and 0.88 ng/mL two hours after the first dose and the dose on the eighth day, respectively.  With timolol maleate ophthalmic solution 0.5% , mean plasma concentrations of timolol were 0.60 ng/mL and 0.89 ng/mL at the same timepoints. </p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_ID_26621E64-335D-490E-9CA3-28B348B61846"></a><a name="section-2.3"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">In a controlled, double-masked, parallel study in 332 patients with untreated intraocular pressures of 22 mm Hg or greater, ISTALOL 0.5% administered once daily (AM) was equivalent to timolol maleate ophthalmic solution 0.5% administered twice daily.  In both groups, mean intraocular pressure decreased from 25 mm Hg at baseline to 18 mm Hg at peak and 19 mm Hg at trough.  ISTALOL was generally well tolerated, and 3% of patients had treatment discontinued for adverse events judged related to treatment.  There was a slight decrease in cardiovascular function consistent with known systemic absorption of a β-adrenoceptor antagonists.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_E173D582-CBB5-4A4C-91B1-40E8E7B1CFC6"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ISTALOL ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> or open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_761C1FFC-2D65-4B80-B384-F4D68AED5392"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ISTALOL is contraindicated in patients with (1) bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; (2) a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; (3) severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (see <a href="#i4i_warnings_ID_6CEAFE4D-EE6D-49CB-8A73-C143537950A9">WARNINGS</a>); (4) <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; (5) second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>; (6) overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <a href="#i4i_warnings_ID_6CEAFE4D-EE6D-49CB-8A73-C143537950A9">WARNINGS</a>); (7) <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; or (8) <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_6CEAFE4D-EE6D-49CB-8A73-C143537950A9"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">As with many topically applied ophthalmic drugs, this drug is absorbed systemically.</p>
<p><span class="Bold">The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration.  For example, severe respiratory reactions and cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and rarely <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in association with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, have been reported following systemic or ophthalmic administration of timolol maleate (see</span><a href="#i4i_contraindications_ID_761C1FFC-2D65-4B80-B384-F4D68AED5392">CONTRAINDICATIONS</a><span class="Bold">).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D11B128A-27CF-4952-902E-68990A60A248"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition of beta-adrenergic receptor blockade may precipitate more severe failure.</p>
<p><span class="Italics">In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></span> continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, ISTALOL should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_8F9FCCD0-493A-454B-8063-3C2A9652A927"></a><a name="section-5.2"></a><p></p>
<h2>Obstructive Pulmonary Disease</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, in which ISTALOL is contraindicated [see <a href="#i4i_contraindications_ID_761C1FFC-2D65-4B80-B384-F4D68AED5392">CONTRAINDICATIONS</a>]) should, in general, not receive beta-blockers, including ISTALOL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_DF6FAB10-849E-4384-9013-3D43EEADBC22"></a><a name="section-5.3"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial.  Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli.  This may augment the risk of general anesthesia in surgical procedures.  Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported.  For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.  If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_11C8CB1E-C0A4-44C4-B297-8CF0E9F3A1EA"></a><a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents.  Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_141A97D5-3607-454F-8634-3BFEA340EEBB"></a><a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blocking agents may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>.  Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_F2216816-699D-4C21-A3CB-B7AA09C70250"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_2FF205A9-C278-49FB-94D4-0FA8C34AADF2"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Because of potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency.  If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with ISTALOL, alternative therapy should be considered. </p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of multiple dose containers of topical ophthalmic products.  These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.  (See PRECAUTIONS, <a href="#i4i_info_patients_ID_3E664D7C-AA49-44A8-877C-D3BB70F97FF0">Information for Patients</a>.) </p>
<p><span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">Choroidal detachment</span> after filtration procedures has been reported with the administration of aqueous suppressant therapy (e.g. timolol).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_95B5DD48-A6DF-4C75-BAD0-8E8B99A73E2C"></a><a name="section-6.1.1"></a><p></p>
<h3>Angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></h3>
<p class="First">In patients with angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, the immediate objective of treatment is to reopen the angle.  This requires constricting the pupil. Timolol maleate has little or no effect on the pupil.  ISTALOL should not be used alone in the treatment of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_3F98A5BA-8A81-4E9A-BC8B-6F5E90351AB4"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h3>
<p class="First">While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens.  Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_8E7CF200-A9B9-434D-BDC4-3963233C66E0"></a><a name="section-6.1.3"></a><p></p>
<h3>Muscle Weaknes</h3>
<p class="First">Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Timolol has been reported rarely to increase <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in some patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or myasthenic symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_3E664D7C-AA49-44A8-877C-D3BB70F97FF0"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. </p>
<p>Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions. (See PRECAUTIONS, <a href="#i4i_precautions_general_ID_2FF205A9-C278-49FB-94D4-0FA8C34AADF2">General</a>.)</p>
<p>Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), they should immediately seek their physician's advice concerning the continued use of the present multidose container.</p>
<p>Patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> should be advised not to take this product. (See <a href="#i4i_contraindications_ID_761C1FFC-2D65-4B80-B384-F4D68AED5392">CONTRAINDICATIONS</a>.)</p>
<p>Patients should be advised that ISTALOL contains benzalkonium chloride which may be absorbed by soft contact lenses.  Contact lenses should be removed prior to administration of the solution.  Lenses may be reinserted 15 minutes following ISTALOL administration.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_3655591A-FD90-4B89-8414-EDE65025FECE"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Although ISTALOL used alone has little or no effect on pupil size, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> resulting from concomitant therapy with ISTALOL and epinephrine has been reported occasionally. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_25549F68-E9FD-421D-8C0C-FFA7A5AACAA3"></a><a name="section-6.3.1"></a><p></p>
<h3>Beta-adrenergic blocking agents</h3>
<p class="First"> Patients who are receiving a beta-adrenergic blocking agent orally and ISTALOL should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.  The concomitant use of two topical beta-adrenergic blocking agents is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_9DD3E109-7527-4744-971E-C01756082364"></a><a name="section-6.3.2"></a><p></p>
<h3>Calcium antagonists</h3>
<p class="First">Caution should be used in the coadministration of beta-adrenergic blocking agents, such as ISTALOL, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.  In patients with impaired cardiac function, coadministration should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_AFC28AA2-1B3B-49CF-B7F0-E022602846EB"></a><a name="section-6.3.3"></a><p></p>
<h3>Catecholamine-depleting drugs</h3>
<p class="First">Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may result in <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E35EEC07-2774-447A-9E94-4B34873BCD80"></a><a name="section-6.3.4"></a><p></p>
<h3>Digitalis and calcium antagonists</h3>
<p class="First">The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_06BEA436-3A79-42D5-A524-37A8051CA9E7"></a><a name="section-6.3.5"></a><p></p>
<h3>Quinidine</h3>
<p class="First">Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with quinidine and timolol, possibly because quinidine inhibits the metabolism of timolol via the P-450 enzyme, CYP2D6.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_9C67340F-B7DE-411A-B20D-C4BB19F7559F"></a><a name="section-6.3.6"></a><p></p>
<h3>Clonidine</h3>
<p class="First">Oral beta-adrenergic blocking agents may exacerbate the <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> which can follow the withdrawal of clonidine.  There have been no reports of exacerbation of <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> with ophthalmic timolol maleate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_765FB681-D8D3-45FE-8C52-AF90F17A6CFC"></a><a name="section-6.3.7"></a><p></p>
<h3>Injectable epinephrine</h3>
<p class="First">(See PRECAUTIONS, <span class="Italics">General, </span><a href="#i4i_section_ID_3F98A5BA-8A81-4E9A-BC8B-6F5E90351AB4"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_B4006656-B38F-4D66-BF51-782187B7EBD2"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a two-year study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose).  Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose. </p>
<p>In a lifetime oral study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and mammary adenocarcinomas in female mice at 500 mg/kg/day, (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day. </p>
<p>The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.</p>
<p>Timolol maleate was devoid of mutagenic potential when tested <span class="Italics">in vivo </span>(mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and <span class="Italics">in vitro </span>in a neoplastic cell transformation assay (up to 100 mcg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 mcg/plate, were associated with statistically significant elevations of revertants observed with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100 (in seven replicate assays), but not in the remaining three <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. In the assays with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test. </p>
<p>Reproduction and fertility studies in rats demonstrated no adverse effect on male or female fertility at doses up to 21,000 times the systemic exposure following the maximum recommended human ophthalmic dose.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_92DD2CF4-127E-481A-85C3-C76EFB4A2352"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_ID_89C8BA96-1B6C-4A04-9F0B-B373AA864019"></a><a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects: Pregnancy Category C:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.</p>
<p>There are no adequate and well-controlled studies in pregnant women. ISTALOL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_87EADFE1-080A-4B60-8850-CA88AA4B467F"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from ISTALOL in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_F17CF34B-BB31-4626-B2D9-B1952D97D416"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_22FC8C7D-84B5-4BDA-8B59-61198EB6A3D3"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_FA94ABF9-5649-4C0D-BC17-22A17139D5F4"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently reported adverse experiences have been burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon instillation in 38% of patients treated with ISTALOL.  Additional events reported with ISTALOL  at a frequency of 4 to 10% include: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival injection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and decreased visual acuity.  </p>
<p>The following additional adverse experiences have been reported less frequently with ocular administration of this or other timolol maleate formulations:</p>
<p>BODY AS A WHOLE<br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</p>
<p>CARDIOVASCULAR<br><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, worsening of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, Raynaud's phenomenon, and <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold hands</span> and feet.</p>
<p>DIGESTIVE<br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p>IMMUNOLOGIC<br><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span>.</p>
<p>NERVOUS SYSTEM/PSYCHIATRIC<br><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, behavioral changes and <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>.</p>
<p>SKIN<br><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> and psoriasiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span><br>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and localized and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>RESPIRATORY<br><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (predominantly in patients with pre-existing bronchospastic disease), <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infections</span>.</p>
<p>ENDOCRINE<br>Masked symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in diabetic patients (see WARNINGS).</p>
<p>SPECIAL SENSES<br>Signs and symptoms of ocular irritation including <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, discharge (e.g., crusting), foreign body sensation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and tearing, and <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>; <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>; decreased corneal sensitivity; <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including refractive changes and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>; pseudopemphigoid; <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">choroidal detachment</span> following filtration surgery (see PRECAUTIONS, <span class="Italics">General</span>); and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p>UROGENITAL<br><span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">Retroperitoneal fibrosis</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and Peyronie's disease. </p>
<p>The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: <span class="Italics">Allergic: </span>Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> with <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>; <span class="Italics">Body as a Whole: </span>Extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, decreased exercise tolerance, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>; <span class="Italics">Cardiovascular: </span>Worsening of <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>; <span class="Italics">Digestive: </span><span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; <span class="Italics">Hematologic: </span>Nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>; <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; <span class="Italics">Endocrine: </span><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>; <span class="Italics">Skin: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; <span class="Italics">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>; <span class="Italics">Nervous System/Psychiatric: </span><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, local <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, diminished concentration, reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on neuropsychometrics; <span class="Italics">Respiratory: </span><span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span>, <span class="product-label-link" type="condition" conceptid="4279071" conceptname="Obstruction of bronchus">bronchial obstruction</span>; <span class="Italics">Urogenital: </span>Urination difficulties.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_1361B068-1A28-4F13-BF47-1AE06FC6C761"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been reports of inadvertent overdosage with ISTALOL ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (see also <a href="#i4i_adverse_effects_ID_FA94ABF9-5649-4C0D-BC17-22A17139D5F4">ADVERSE REACTIONS</a>).</p>
<p>An <span class="Italics">in vitro </span>hemodialysis study, using <span class="Sup">14</span>C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> showed that timolol did not dialyze readily.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_2110C228-072C-4909-AC1A-80E321911E8C"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">ISTALOL ophthalmic solution is available in a concentration of 0.5 percent.  The starting dose is one drop of 0.5 percent ISTALOL in the affected eye(s) once a day in the AM.  If the patient's intraocular pressure is not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted.  The concomitant use of two topical beta-adrenergic blocking agents is not recommended.  (See PRECAUTIONS, <span class="Italics">Drug Interactions, <a href="#i4i_section_ID_25549F68-E9FD-421D-8C0C-FFA7A5AACAA3">Beta-adrenergic blocking agents</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_66371265-39C4-4AB5-93C2-230A0EDE04A0"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sterile Ophthalmic Solution ISTALOL is a clear, colorless to light yellow solution. ISTALOL Ophthalmic Solution, 0.5% supplied in a white LDPE bottle with 15 mm LDPE yellow cap and 15 mm LDPE white dropper tip as follows:</p>
<p>NDC 67425-003-50          5 mL in 10 mL container</p>
<p>NDC 67425-003-12          2.5 mL in 7.5 mL container</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_4B668081-6598-4488-8B9B-BA440424342B"></a><a name="section-10.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 15-25°C (59-77°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f2642dce-4885-6c2f-7cd7-ffb465b3ed19"></a><a name="section-11"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 67425-003-50<br><span class="Bold">Istalol </span>(timolol maleate ophthalmic solution) 0.5%<br>Sterile 5 mL<br>Rx Only<br>Once Daily</p>
<div class="Figure"><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=80fa20dc-b181-48be-83ce-d66a83753878&amp;name=Istalol%205mL%20Carton.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ISTALOL  		
					</strong><br><span class="contentTableReg">timolol maleate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67425-003</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>timolol maleate</strong> (timolol) </td>
<td class="formItem">timolol</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Monobasic, Monohydrate</strong></td>
<td class="formItem">0.9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium sorbate</strong></td>
<td class="formItem">4.7 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">5.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67425-003-50</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:67425-003-12</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021516</td>
<td class="formItem">08/01/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>ISTA PHARMACEUTICALS, INC.
							(957212350)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>ISTA PHARMACEUTICALS, INC. (957212350)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ISTA PHARMACEUTICALS, INC.</td>
<td class="formItem"></td>
<td class="formItem">957212350</td>
<td class="formItem">ANALYSIS(67425-003)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BAUSCH &amp; LOMB PHARMACEUTICALS, INC</td>
<td class="formItem"></td>
<td class="formItem">807927397</td>
<td class="formItem">MANUFACTURE(67425-003)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2004<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>49b5de8f-1a37-4d82-7d6d-ab8ab0d57e66</div>
<div>Set id: 80fa20dc-b181-48be-83ce-d66a83753878</div>
<div>Version: 2</div>
<div>Effective Time: 20040406</div>
</div>
</div> <div class="DistributorName">ISTA PHARMACEUTICALS, INC.</div></p>
</body></html>
